The problem we are working on
Alzheimer's disease is not a sudden event. The underlying neurodegeneration begins years — sometimes decades — before the first clinical symptom appears. By the time a diagnosis is made, the window for intervention has often already narrowed significantly.
The field has made substantial progress in identifying biological markers: tau protein accumulation, amyloid deposits, neuroimaging signals. But these require clinical infrastructure that most people never access preventively.
NeuroFlex is exploring a different layer: digital behavioral biomarkers — signals that may emerge in everyday interactions with digital tools, measurable longitudinally and at scale.
What NeuroFlex is building
NeuroFlex is being developed in two parallel tracks:
Today: a platform prototype with a free cognitive wellness Android application as its first tool. Brain training games, daily habit support, an alarm system, and structured activities across six domains — Train, Drink, Move, Eat, Connect, Relax. No ads. No data collection. Designed for anyone who wants to stay cognitively engaged.
Tomorrow: the same platform evolves into a longitudinal behavioral research infrastructure. The everyday interactions captured through its tools — with appropriate consent and privacy infrastructure — become a structured behavioral dataset. Not isolated test sessions, but trajectories across months and years.